Preliminary Results Of The First-In-Human Study Of Nexi-001, A Multi-Antigen Specific Cd8+T Cell Product, In Acute Myeloid Leukemia (Aml) Patients With Relapsed Disease After Allogeneic Hematopoietic Cell Transplantation (Allo-Hsct) Demonstrate Early Signs Of Safety, Tolerability And Robust Immune Responses